Cantuzumab

Cantuzumab is a type of monoclonal antibody that was developed for the treatment of cancer. It is also known as Cantuzumab mertansine and was developed by Immunogen.

History[edit | edit source]

Cantuzumab was developed by the biotechnology company Immunogen. It was designed to target the CanAg antigen, which is found on the surface of many types of cancer cells, including colorectal cancer, pancreatic cancer, and non-small cell lung cancer.

Mechanism of Action[edit | edit source]

Cantuzumab works by binding to the CanAg antigen on the surface of cancer cells. This binding triggers the release of a toxic substance called maytansinoid, which kills the cancer cells.

Clinical Trials[edit | edit source]

Cantuzumab has been tested in several clinical trials. In a Phase I trial, it was found to be safe and well-tolerated. However, in a Phase II trial, it did not show significant efficacy in patients with colorectal cancer.

Side Effects[edit | edit source]

The most common side effects of Cantuzumab include nausea, vomiting, and diarrhea. Other side effects can include fatigue, anemia, and neutropenia.

Future Research[edit | edit source]

Future research on Cantuzumab may focus on its potential use in combination with other cancer treatments, or on its use in other types of cancer.

See Also[edit | edit source]

Cantuzumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.